These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Real or alleged risks of clofibrate derivatives and certain risks of their prohibition]. de Gennes JL Nouv Presse Med; 1979 Mar; 8(15):1223-5. PubMed ID: 375186 [No Abstract] [Full Text] [Related]
4. Cholesterol, clofibrate and ischaemic heart disease. Facts and emotions around. Fejfar Z Cor Vasa; 1979; 21(6):377-9. PubMed ID: 397875 [No Abstract] [Full Text] [Related]
5. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J; 1978 Oct; 40(10):1069-118. PubMed ID: 361054 [No Abstract] [Full Text] [Related]
6. Hypolipaemic drugs and coronary heart disease. Howard AN J Clin Pathol Suppl (R Coll Pathol); 1975; 9():106-14. PubMed ID: 783209 [No Abstract] [Full Text] [Related]
7. [Clinical trials of cholestyramine alone and in combination with clofibrate in hypercholesterolemia]. Carlson LA; Olsson AG; Orö L; Rössner S Lakartidningen; 1974 Sep; 71(36):3289-91. PubMed ID: 4605566 [No Abstract] [Full Text] [Related]
8. [Study of clofibrate. The opinion of Prof. D. Kritchevsky]. Fabbrocini V Minerva Cardioangiol; 1980 Nov; 28(11):759-60. PubMed ID: 7231692 [No Abstract] [Full Text] [Related]
9. Clofibrate and niacin in coronary heart disease. JAMA; 1975 Jan; 231(4):360-81. PubMed ID: 1088963 [No Abstract] [Full Text] [Related]
10. [Is hypolipemic treatment effective as a preventive measure?]. Rywik S Przegl Lek; 1989; 46(7):619-23. PubMed ID: 2685917 [No Abstract] [Full Text] [Related]
11. [3-year treatment of hypercholesteremia with clofibrate under conditions of double-blind method]. Metelitsa VI; Dokuchaeva EA; Chubukova AL; Iliushina IP; Ostrovskaia TP Ter Arkh; 1978; 50(1):45-50. PubMed ID: 345516 [No Abstract] [Full Text] [Related]
13. Cholesterol, coronaries, clofibrate and death. Oliver MF N Engl J Med; 1978 Dec; 299(24):1360-2. PubMed ID: 362204 [No Abstract] [Full Text] [Related]
14. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. Coronary Drug Project Research Group N Engl J Med; 1980 Oct; 303(18):1038-41. PubMed ID: 6999345 [TBL] [Abstract][Full Text] [Related]
15. [Effect of a new lipid-reducing preparation (Etofibrat) on hyperlipoproteinemia type II. 2]. Knüchel F Med Welt; 1974 Nov; 25(44):1810-2. PubMed ID: 4372508 [No Abstract] [Full Text] [Related]
16. Prevention of coronary heart disease--propaganda, promises, problems, and prospects. Oliver MF Circulation; 1986 Jan; 73(1):1-9. PubMed ID: 3510083 [No Abstract] [Full Text] [Related]
17. [Etofibrate and clofibrate in a double-blind trial on patients with raised serum-lipid levels (author's transl)]. Kaffarnik H; Schneider J; Haase W Dtsch Med Wochenschr; 1975 Nov; 100(48):2486-8. PubMed ID: 1104303 [TBL] [Abstract][Full Text] [Related]
18. Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man. Cohn K; Sakai FJ; Langston MF Am Heart J; 1975 May; 89(5):591-8. PubMed ID: 1091127 [TBL] [Abstract][Full Text] [Related]
20. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. Br Med J; 1971 Dec; 4(5790):767-75. PubMed ID: 4943605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]